与最佳医疗疗相比,跨导管三管干预:随机对照试验的元分析
Carolina Hoyos1, Sunil Upadhaya2, Ahmad Jabri3
1Department of Medicine, Louisiana State University Health and Sciences Center, 2390 W Congress Street, Lafayette, LA, 70503, United States of America.
概括
通过导管三门干预 (TTVI) 与最佳医疗治疗相比,并没有显著降低死亡率或心力衰竭住院. 然而,TTVI在高风险患者中改善了功能类,生活质量和三腹的严重程度.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 膜心脏疾病 膜心脏疾病
背景情况:
- 三回 (TR) 是一种普遍的门疾病,与显著的发病率和死亡率有关.
- 通过导管三门干预 (TTVI) 为TR的高风险患者提供了一种新的治疗方法.
- 在现有的随机对照试验 (RCT) 中,有限的样本大小阻碍了对TTVI疗效的最终结论.
研究的目的:
- 系统地审查和比较TTVI与最佳医疗疗 (OMT) 的临床结果.
- 评估TTVI对TR患者死亡率,心力衰竭住院和生活质量的影响.
主要方法:
- 从2000年1月到2025年6月发表的比较TTVI和OMT的RCT的系统审查.
- 在PubMed,Cochrane和Embase数据库中进行了搜索.
- 主要结局:全因死亡率和心力衰竭住院 (HFH);次要结局:心血管死亡,TR严重程度,NYHA类和KCCQ得分.
主要成果:
- 对3项涉及1264名患者的RCT进行分析 (TTVI:696;OMT:568).
- 在TTVI和OMT组之间,在一年内全因死亡率,HFH或心血管死亡率没有显著差异.
- TTVI组在NYHA功能类,堪萨斯城心肌病问卷 (KCCQ) 分数显著改善,并减少了严重TR发病率.
结论:
- 然而,TTVI并没有在统计学上显著地减少所有原因的死亡率或HFH.
- 在功能类,生活质量和TR严重程度方面,TTVI表现出了显著的改善.
- TTVI支持在某些患有三腹吐的高风险患者中使用它.
相关概念视频
Mitral Stenosis III: Medical Management
239
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
239
Mitral Regurgitation III: Medical Management
268
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
268
Aortic Regurgitation III: Medical Management
388
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
388
Mitral Valve Prolapse II: Assessment and Management
406
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
406
Pericarditis III: Medical Management
302
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
302
Acute Coronary Syndrome IV: Interprofessional Care
214
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
214


